These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 10683191

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W, Martorana PA, Schölkens BA.
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC, Pullen MA, Edwards RM, Brooks DP.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [Abstract] [Full Text] [Related]

  • 7. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo.
    Sun W, Wainwright CL.
    Coron Artery Dis; 1994 Jun; 5(6):541-50. PubMed ID: 7952414
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium.
    Kitakaze M, Node K, Minamino T, Asanuma H, Ueda Y, Kosaka H, Kuzuya T, Hori M.
    J Mol Cell Cardiol; 1998 Nov; 30(11):2461-6. PubMed ID: 9925380
    [Abstract] [Full Text] [Related]

  • 9. Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway.
    Vegh A, Szekeres L, Parratt J.
    Br J Pharmacol; 1992 Nov; 107(3):648-52. PubMed ID: 1472963
    [Abstract] [Full Text] [Related]

  • 10. The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs.
    Végh A, Parratt JR.
    Br J Pharmacol; 2002 Dec; 137(7):1107-15. PubMed ID: 12429584
    [Abstract] [Full Text] [Related]

  • 11. Delayed cardioprotective effects of exercise in dogs are aminoguanidine sensitive: possible involvement of nitric oxide.
    Babai L, Szigeti Z, Parratt JR, Végh A.
    Clin Sci (Lond); 2002 Apr; 102(4):435-45. PubMed ID: 11914106
    [Abstract] [Full Text] [Related]

  • 12. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 13. Noradrenaline, infused locally, reduces arrhythmia severity during coronary artery occlusion in anaesthetised dogs.
    Végh A, Parratt JR.
    Cardiovasc Res; 2002 Jul; 55(1):53-63. PubMed ID: 12062708
    [Abstract] [Full Text] [Related]

  • 14. Modification by bradykinin B2 receptor blockade of protection by pacing against ischaemia-induced arrhythmias.
    Kaszala K, Végh A, Papp JG, Parratt JR.
    Eur J Pharmacol; 1997 Jun 05; 328(1):51-60. PubMed ID: 9203568
    [Abstract] [Full Text] [Related]

  • 15. [ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].
    Schölkens BA, Linz W.
    Klin Wochenschr; 1991 Jun 05; 69 Suppl 24():1-5. PubMed ID: 1865630
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart.
    Kozlovski VI, Lomnicka M, Jakubowski A, Chlopicki S.
    Pharmacol Rep; 2007 Jun 05; 59(4):421-7. PubMed ID: 17901571
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
    Bani M, Colantoni A, Guillaume M, Macchi F, Moroni G, Persiani S.
    Br J Clin Pharmacol; 2000 Oct 05; 50(4):338-49. PubMed ID: 11012557
    [Abstract] [Full Text] [Related]

  • 18. Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion.
    Végh A, György K, Rastegar MA, Papp JG, Parratt JR.
    Eur J Pharmacol; 1999 Oct 08; 382(2):81-90. PubMed ID: 10528142
    [Abstract] [Full Text] [Related]

  • 19. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs.
    Rastegar MA, Végh A, Papp JG, Parratt JR.
    Cardiovasc Drugs Ther; 2000 Oct 08; 14(5):471-9. PubMed ID: 11101194
    [Abstract] [Full Text] [Related]

  • 20. Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase.
    Kis A, Végh A, Papp J, Parratt J.
    Br J Pharmacol; 1999 Aug 08; 127(7):1545-50. PubMed ID: 10455308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.